Cancer drug keytruda tested as possible treatment for long COVID brain fog

NCT ID NCT07388550

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 36 times

Summary

This early-stage trial tests whether a single dose of pembrolizumab (Keytruda), a drug used for cancer, can safely reduce long-term neurological symptoms like brain fog and dizziness in people with long COVID. Fifteen adults who had COVID-19 at least six months ago and still have nerve-related symptoms will receive one IV dose and be followed for six months. The main goal is to check safety, but researchers will also look for signs of improvement in thinking, movement, and daily function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pembrolizumab (Keytruda)
What this could lead to
If it works, this could point toward a treatment for brain fog, dizziness, and other lasting neurological symptoms after COVID-19.
What could go wrong
This is a very early, small Phase 1 safety trial with only 15 people, so it is not designed to prove the drug works. Pembrolizumab can cause immune-related side effects, and its safety for long COVID is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-ACUTE COVID-19 SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.